Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs in oncology and infectious disease, continues to attract investments that will fund research and clinical trials regarding the use of the company’s lead drug candidate, IP-001. The latest financing tranche, which was raised through the sale of the company’s authorized Series B Preferred Stock, has yielded $21.4 million…
